VivoSeq
Other

Endothelial Dysfunction

79

Pipeline Programs↗

6

Active Trials↗

37

Companies Involved↗

Endothelial Dysfunction is a moderately active landscape with 79 programs across 37 companies. The most active players are Vicore Pharma AB, Pfizer, McGuff Pharmaceuticals, Inc.. 30 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

15/100

Mech. Concentration

10/100

Completion Rate

87/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vicore Pharma AB

1 program

Phase 1Pfizer logo

Pfizer

1 program

Phase 1M

McGuff Pharmaceuticals, Inc.

1 program

Phase 1V

Viatris Specialty LLC

2 programs

Phase 2BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

1 program

Phase 2H

Han Wha Pharma Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical18

Estradiol

Novo Nordisk

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Pravastatin

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Celebrex

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

GLP-1

Rigshospitalet, Denmark

Phase 19

Galantamine

Wim Janssens

Dapagliflozin

AstraZeneca

Liraglutide

Novo Nordisk

Rosiglitazone

Alnylam Pharmaceuticals

Gemfibrozil

Pfizer

Phase 216

Aliskiren

Tibotec Pharmaceuticals, Ireland

Iloprost

BTG International Inc.

Pentoxifylline

Validus Pharmaceuticals

Intracoronary Infusion of Acetylcholine

Azienda Ospedaliera San Camillo Forlanini

Ghrelin

University of Aarhus

Phase 36

Metformin

EMD Serono

Nitric Oxide

Mallinckrodt

Valsartan

Novartis

Febuxostat

Takeda

Sitagliptin

Zydus Therapeutics Inc.

Approved30

Ticagrelor

AstraZeneca

Semaglutide

Novo Nordisk

Losartan

Organon and Co

Saxagliptin

AstraZeneca

Allopurinol

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

95%

Small molecule

84 of 88 classified programs — the dominant modality here.

5%ALL OTHERSPeptide33%Cell therapy11%

Small molecule leads; the ring shows all 88 classified programs, each share of the total. Modality classified for 100% of 92 pipeline programs.

Analysis

Trial Status

79

clinical trials

Completed48 · 61%
Unknown status18 · 23%
Terminated6 · 8%
Recruiting4 · 5%
Active, not recruiting2 · 3%
Withdrawn1 · 1%

Clinical Trials

Trial Activity

79 trials

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
Recruiting·AAurion Biotech·Phase 3·NCT07368959·120 enrolled
EndoPAT Device for Endothelial Dysfunction in ED
Recruiting·UUniversity of California, Irvine·N/A·NCT06720597·120 enrolled
Vascular Endothelial Dysfunction in Sleep Apnea
Recruiting·—·Phase 1·NCT05289063·110 enrolled
MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction
Recruiting·UUniversitas Padjadjaran·Phase 1/2·NCT07183384·80 enrolled
Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans
Active, not recruiting·VVanderbilt University Medical Center·Phase 1/2·NCT04769206·46 enrolled
Effect of a Daily Nitric Oxide-Stimulating Supplement on Plasma PAI-1 Levels: a Six-Week, Open-Label Clinical Trial
Active, not recruiting·UUniversity of California, Los Angeles·Preclinical·NCT07469475·35 enrolled
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
Completed·—·Phase 2/3·NCT02866214·57 enrolled
Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 4·NCT00240422·96 enrolled
Endothelial Dysfunction and Diabetes
Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01097551·38 enrolled
A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
Completed·—·Phase 4·NCT00675987·53 enrolled
Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
Completed·GGulhane School of Medicine·Phase 4·NCT01135615·100 enrolled
Mechanisms of Endothelial Dysfunction in Type 2 Diabetes
Completed·UUniversity Hospital, Rouen·N/A·NCT02311075·48 enrolled
Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients
Completed·—·N/A·NCT04128878·12 enrolled
Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome
Completed·Novartis logoNovartis·Phase 2·NCT00417170·48 enrolled
Effects of Pitavastatin on Monocyte, Endothelial Dysfunction and HDL-C in Subjects With Metabolic Syndrome
Completed·KKowa Research Europe·Phase 1·NCT01595828·14 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)